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Enhanced phasic GABA inhibition during the
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Ischaemic stroke is the leading cause of severe long-term disability yet lacks drug therapies that promote the repair phase of
recovery. This repair phase of stroke occurs days to months after stroke onset and involves brain remapping and plasticity within
the peri-infarct zone. Elucidating mechanisms that promote this plasticity is critical for the development of new therapeutics with a
broad treatment window. Inhibiting tonic (extrasynaptic) GABA signalling during the repair phase was reported to enhance
functional recovery in mice suggesting that GABA plays an important function in modulating brain repair. While tonic GABA
appears to suppress brain repair after stroke, less is known about the role of phasic (synaptic) GABA during the repair phase. We
observed an increase in postsynaptic phasic GABA signalling in mice within the peri-infarct cortex specific to layer 5; we found
increased numbers of a1 receptor subunit-containing GABAergic synapses detected using array tomography, and an associated
increased efficacy of spontaneous and miniature inhibitory postsynaptic currents in pyramidal neurons. Furthermore, we demon-
strate that enhancing phasic GABA signalling using zolpidem, a Food and Drug Administration (FDA)-approved GABA-positive
allosteric modulator, during the repair phase improved behavioural recovery. These data identify potentiation of phasic GABA
signalling as a novel therapeutic strategy, indicate zolpidem’s potential to improve recovery, and underscore the necessity to
distinguish the role of tonic and phasic GABA signalling in stroke recovery.
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Introduction
Mechanisms that promote brain repair and recovery offer
novel drug targets for stroke, a major cause of adult dis-
ability with very few therapeutic options. The majority of
available treatments target the acute phase of ischaemic
stroke to establish reperfusion and reduce brain cell
death, but must be administered within a few hours of
stroke onset (Allen et al., 2012; Berkhemer et al., 2015).
Unfortunately, 510% of stroke patients can benefit from
such treatments due, in large part, to late referral to the
hospital and inability to meet other eligibility criteria (Allen
et al., 2012). In contrast to the acute stage, the repair phase
of stroke occurs days to months after the stroke incident
and thus offers an expanded therapeutic window.
Importantly, brain plasticity and remapping during the
repair phase play a major role in the spontaneous recovery
observed after stroke in both humans and rodents. For ex-
ample, reorganization and rewiring of surviving circuits,
including those adjacent to the stroke site (i.e. the peri-in-
farct), enable the healthy portion of the brain to compen-
sate for the functions of the stroke-damaged area (Nudo
et al., 1996; Dijkhuizen et al., 2001; Carmichael, 2006;
Murphy and Corbett, 2009). Deciphering the specific syn-
aptic changes involved in the repair phase of stroke, and
identifying those that can be modulated to improve out-
come, is paramount to identifying novel therapeutics to
promote functional recovery.
GABA type A receptor (GABAAR)-mediated inhibition is
a critical component in the development and plasticity of
cortical map boundaries in the normal brain (Zheng and
Knudsen, 2001; Derdikman et al., 2003; Hensch and
Stryker, 2004; Foeller et al., 2005). The GABAergic signal-
ling mechanisms that modulate cortical map boundaries in
the normal brain may also mediate the stroke-induced cor-
tical remapping required for functional recovery. Indeed, a
role for GABA in plasticity-related recovery was suggested
by Clarkson et al. (2010) who observed an increase tonic
GABA signalling—a form of GABAAR-mediated inhibition
that relies on extrasynaptic GABAAR’s—in the peri-infarct
cortex during the repair phase (Clarkson et al., 2010).
These authors found that systemically reducing tonic
GABA-mediated inhibition during this phase improved re-
covery, suggesting that the post-stroke increase in tonic in-
hibition is detrimental to recovery of function. Phasic
GABA inhibition is the classical mode of GABA signalling
mediated, largely, by GABAARs at the synapse. While
enhancing phasic GABA is known to be neuroprotective
and reduce excitotoxic neuron death in the acute phase
of stroke (Lyden and Hedges, 1992; Green et al., 2000),
its role in plasticity-related recovery during the repair phase
of stroke is largely unknown. Specific GABAARs mediate
each form of GABA signalling, which renders phasic and
tonic inhibition differentially susceptible to pharmaco-
logical manipulation. GABAARs are heteropentameric pro-
teins, with synaptic receptors generally consisting of two ,
two b, and a g subunit (Fritschy and Mohler, 1995). While
multiple subunit isoforms have been identified (six , four
b, and three g isoforms), GABAARs containing the 1 sub-
unit are the most highly expressed synaptic GABAAR in the
mammalian brain and are thought to mediate the majority
of phasic inhibition (Fritschy and Mohler, 1995). By con-
trast, tonic inhibition is mediated by distinct receptor het-
eromers containing either an 5 isoform or 4 isoform and
a  subunit substituted for g (Farrant and Nusser, 2005).
Decreased expression of synaptic GABAAR subunits
(Schiene et al., 1996; Neumann-Haefelin et al., 1998; Qu
et al., 1998; Redecker et al., 2000; Jolkkonen et al., 2003),
combined with studies reporting decreased phasic GABA
signalling in layer 2/3 pyramidal neurons at the onset of
functional recovery (Neumann-Haefelin et al., 1995;
Clarkson et al., 2010), suggest that phasic GABA signalling
is reduced in the repair phase of stroke, but the significance
of this for recovery is not known. Another study found no
change in GABA signalling in layer 2/3 in the first 3 days
after stroke (Mittmann et al., 1998). Importantly, recent
case reports demonstrate that treatment with zolpidem,
an FDA-approved GABAA positive allosteric modulator
with highest affinity for 1-containing receptors (Crestani
et al., 2000), improved brain function in patients with
severe brain injuries, including stroke (Shames and Ring,
2008; Hall et al., 2010). Although it is hard to extrapolate
the involvement of phasic GABA in brain recovery from
these patient studies, these reports suggest that, unlike
tonic inhibition, enhanced GABAAR1-mediated phasic sig-
nalling in the repair phase may be beneficial for recovery.
Furthermore, little is known about the overall changes in
inhibitory signalling in cortical circuitry. For instance, it is
unknown how stroke affects phasic GABA signalling in all
the different cell types across the structurally organized
layers of the somatosensory cortex. This information is cru-
cial to understand the functional implication(s) of modified
phasic GABA signalling. For example, modifying signalling
in pyramidal layer 5 neurons, which provide the major
output to subcortical structures, may have a different func-
tional consequence than modifying layer 2/3 pyramidal
neurons, which are primarily dedicated to cortico-cortical
communication.
Given that GABAAR1 mediates the majority of phasic
inhibition, and the recent clinical evidence for its potential
role in brain repair, we used a combination of approaches
to examine cortical layer- and cell-specific phasic GABA
signalling in the repair phase of stroke and to determine
the role of GABAAR1-mediated phasic inhibition in stroke
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recovery. We focused on layer 5, the major output layer,
and layer 2/3 as this is where Clarkson et al. (2010)
observed effects on tonic GABA signalling after stroke.
We used array tomography, a high-resolution imaging
method (Micheva and Smith, 2007; Micheva et al.,
2010), to identify cortical layer-specific changes in
GABAA-R1-containing synapse numbers after stroke. We
performed intracellular whole-cell recordings to determine
if the structural synaptic changes observed by array tom-
ography were associated with a functional change in phasic
GABAAR inhibition and to identify which cell types
undergo synaptic alterations. Last, we modulated
GABAA-R1-mediated phasic inhibition to determine its
effect on functional recovery. We provide the first evidence
that phasic GABA signalling is increased in the peri-infarct
cortex during the onset of post-stroke functional recovery.
Furthermore, the increase in phasic GABA signalling is spe-
cific to layer 5. Lastly, we found, in contrast to tonic GABA
signalling, that further enhancing phasic GABA signalling
during the repair phase is beneficial for stroke recovery.
Materials and methods
See the online Supplementary material for further details. All
animal procedures were approved by the Stanford University
Administrative Panel on Laboratory Animal Care.
Stroke models
Animals were housed three to five per cage under a normal
light/dark cycle. Adult (10–13 weeks old) male C57BL/6J mice
(Jackson), weighing 25–30 g, were anaesthetized with isoflur-
ane (2.5% in a mixture of 1 l/min of air and 0.2 l/min of
oxygen). Core body temperature was measured by a rectal
probe and maintained at 37C throughout the surgery.
Mortality rate was zero.
Distal middle cerebral artery occlusion model
The distal middle cerebral artery was exposed through a burr
hole between the left eye and ear, cauterized, and cut just
above the rhinal fissure. Sham animals only received the skin
incision.
Photothrombotic model
After fixation in a stereotactic frame (David Kopf Instruments)
the skull was exposed by midline incision of the skin. Rose
Bengal (10mg/ml in normal saline) was intraperitoneal injected
(80mg/kg). Five minutes later the exposed skull was illumi-
nated (directly on the skull) for 15min using a cold light
source with an aperture of 2.4mm, focused 0.0mm anterior
and 1.8mm right of the Bregma.
Lesion size assessment
Tissue processing
For Day 2 post-stroke tissue, mice were sacrificed by deep
anaesthesia and 2-mm thick coronal brain sections cut and
stained with 2% triphenyltetrazolium chloride (TTC). For
Days 7 and 28 post-stroke tissue, mice were perfused transcar-
dially with heparinized phosphate-buffered saline (PBS) fol-
lowed by 3% paraformaldehyde (PFA). Coronal sections
were cut and 1 in every 16 sections (five sections per brain;
30 mm) was stained using the high-contrast silver stain method
(Arac et al., 2011) (Day 7 brains) or one in eight sections
(eight sections per brain: 20 mm) were stained with Cresyl
violet (Day 28 brains).
Lesion size measurement
Brain sections were scanned (Epson Expressions 10000XL flat-
bed scanner) and the total ipsilateral, contralateral and the
infarct areas were measured in a blinded manner using
ImageJ (NIH). Lesion size was calculated as: % lesion
size = 100  (total contralateral cortex area healthy ipsilat-
eral cortex area) / (total contralateral cortex area).
Array tomography
Array tomography was carried out as described (Micheva and
Smith, 2007; Micheva et al., 2010). Following perfusion with
PFA the peri-infarct tissue was dissected out, ribbons of 30–35
serial ultrathin (70 nm) sections cut, stained for synaptic mar-
kers, and imaged. To analyse synapses in a similar brain
region between animals, the following criteria were set
(Supplementary Fig. 1A–C): (i) we defined the peri-infarct
cortex as the cortical tissue within 0.8mm from the medial
edge of the lesion; (ii) synapses were analysed within the
same cortical region, at + 0.26 to + 0.02mm anterior to
Bregma on sections that contained the anterior commissure;
and (iii) only stroke-injured animals with lesions with a
medial edge within 3.0  0.3mm from the midline were con-
sidered for analysis. The number of glutamatergic and
GABAergic synapses, defined by the co-localization of pre-
and postsynaptic markers (Table 1), was quantified using
MATLAB.
Whole-cell patch-clamp
electrophysiology
Whole-cell patch clamp recordings from acute neocortical
brain slices were performed to evaluate GABA-mediated syn-
aptic signalling in the peri-infarct cortex. Slice preparation and
recordings were performed as described (Paz et al., 2010,
2013), and done blinded to the experimental group for the
stroke-injured animals treated with zolpidem versus vehicle.
Spontaneous and miniature postsynaptic inhibitory current
(IPSC) recordings were performed in the same neocortical
region as the array tomography analysis (see above) and
within 800mm from the edge of the lesion. Neocortical neu-
rons were visually identified using differential contrast optics
with a Zeiss (Oberkochen) Axioskop microscope and an infra-
red video camera. Recording electrodes made of borosilicate
glass had a resistance of 2.5–6 MV when filled with intracel-
lular solution (Supplementary material). Neurons were
clamped at 70mV and GABAA receptor-mediated spontan-
eous IPSC events were pharmacologically isolated by bath ap-
plication of the ionotropic glutamate receptor blocker
kynurenic acid (1mM, Abcam); whereas miniature IPSCs
were isolated using tetrodotoxin (0.5 mM TTX, Abcam) and
kynurenic acid (1mM, Abcam). At the end of the recordings,
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whole slices were fixed with PFA solution overnight and pro-
cessed using immunofluorescent staining for biocytin and glial
fibrillary acidic protein (Supplementary material). Firing pat-
tern and cell morphology of the biocytin-labelled cells were
used to distinguish pyramidal cells from fast-spiking inter-
neurons. Access resistance was monitored in all the recordings,
and cells were included for analysis only if the access resistance
was 518 MV and the change of resistance was 520% over
the course of the experiment. See Supplementary material for
non-invasive membrane potential recordings.
In vivo drug administration
Zolpidem (Sigma-Aldrich) was dissolved in dimethylsulphox-
ide (DMSO) and then diluted 1:2 in 0.9% saline, to give a
final concentration of 5mM zolpidem (in 33% DMSO final).
ALZET-1002 pumps containing zolpidem or vehicle (33%
DMSO in 0.9% saline) were implanted subcutaneously at 3
days after stroke, under 2.0–2.5% isoflurane anaesthesia, and
replaced every 2 weeks. The pumps delivered a zolpidem dose
of 9.2mg/24 h. Although detailed pharmacokinetic data for
zolpidem are not available for mouse, based on the published
information for rat (Garrigou-Gadenne et al., 1989) we calcu-
lated that this dosing schedule results in subsedative blood
levels (Benavides et al., 1993; Vlainic and Pericic, 2010;
Farkas et al., 2013) of 20 nM. In acute administration stu-
dies, 0.1mg/kg or 1mg/kg of zolpidem was administered by
intraperitoneal injection at 1 h and 24 h post-stroke. No ani-
mals died after zolpidem treatment. One animal with a photo-
thrombotic-induced lesion died after vehicle treatment; its data
were excluded from analysis.
Behaviour analysis
The adhesive tape removal test was used to measure forepaw
sensorimotor function (Bouet et al., 2009) and the rotating
beam test was used to measure more gross motor and sensory
function (Cheng et al., 2014). All behaviour testing was run
during the light cycle in a blinded manner. For both tests mice
were trained for 5 days prior to stroke surgery and a baseline
recorded 1 day prior to stroke. Post-stroke mice were assessed
at Day 2 and at Weeks 1, 2, 3 and 4. For the tape test, a small
piece of adhesive tape (3mm  4mm) was placed on each
forepaw, and the time needed to contact and remove the
tape from each forepaw was recorded. The test was stopped
after 2 mins if the mice did not remove the tape in this time.
Two runs were performed at each time point and the average
score used in the analysis. Animals were randomized to the
different groups based on their Day 2 (pretreatment score)
such that the average and distribution of the scores was similar
between the appropriate groups. Animals were excluded from
the study if the time-to-contact at Day 2 post-stroke was
520 s as this indicated a minor stroke-related deficit that re-
sults in rapid spontaneous recovery to baseline within a few
days. If animals did not complete the test on both the ‘affected’
and ‘unaffected’ paw after Day 2 post-stroke this was taken as
a sign of lack of motivation rather than a sensorimotor deficit,
and this trial was excluded from analysis. This was only
observed at one time point in two vehicle-treated animals
with the photothromobotic stroke. For the rotating beam test
the mice were placed on a fibreglass beam (length 120 cm,
diameter 13mm) that rotated at 3 rpm. The distance travelled
and the speed of traversing was obtained. Three trials were
performed at each time point and the average of the fastest
two speeds was used for analysis. Randomization of the ani-
mals was based on their tape test score, as this was our pri-
mary behaviour test. No test was run on Day 2 following
photothrombotic-induced stroke as the animals were unable
to stay on the beam at this time point.
Data acquisition and statistical
analysis for electrophysiology
For data acquisition and analysis, we used a Digidata 1320
digitizer and pClamp9 (Molecular Devices). We amplified the
signals with Multiclamp (Molecular Devices), and sampled and
filtered them at 10 kHz. We detected and analysed spontan-
eous IPSCs with wDetecta, a custom postsynaptic current de-
tection program (http://huguenardlab.stanford.edu/apps/
wdetecta/). We detected and analysed miniature IPSCs with
Mini Analysis Program (www.synaptosoft.com/MiniAnalysis).
Numerical values are given as means  SEM unless stated
otherwise. For electrophysiology data tables (Supplementary
Tables 1–5), we calculated average events per cell and com-
pared all injured and non-injured cells by performing one-way
ANOVA (parametric) or the Kruskal-Wallis one-way ANOVA
on ranks (non-parametric). For cumulative probability distri-
butions, each cohort population is composed by a random
selection of 100 events from each cell (i.e. 1200 events from
12 cells) and compared all injured and non-injured event
populations using the Kolmogoroff-Smirnoff test (non-
parametric) to determine statistical significance (P50.005).
We assessed normality and distribution equality using
Kolmogorov-Smirnoff goodness-of-fit procedure and variance
ratio test, respectively. We performed statistical analyses with
Sigma Stat 3.5 and Origin 7.0 (Microcal Software). For IPSCs,
we fitted the peak-to-baseline decay phase of the resulting cur-
rent trace by a single exponential function.
Statistical analysis for array tomo-
graphy and behavioural data
All values are expressed as mean  SEM across animals, and
data were analysed using GraphPad Prism software (v4.0c).
Table 1 Classification of glutamatergic and GABAergic
synapses based on the co-localization of pre- and post-
synaptic markers
Synapse type Presynaptic markers Postsynaptic
marker
Glutamate Synapsin + PSD95
(i) VGluT1; or
(ii) VGluT2; or
(iii) VGluT1 + VGluT2
GABA Synapsin + GAD + VGAT GABAAR1
Three glutamatergic subtypes (i–iii) were defined by the presence or absence of
VGluT1 and VGluT2. As the majority of GABAA synapses contain GABAA-R1 we
chose this subunit as our GABA synapse postsynaptic marker. VGluT = vesicular
glutamate transporter; GABAA-R1 = 1 subunit of the GABA receptor;
GAD = glutamate decarboxylase; VGAT = vesicular GABA transporter;
PSD95 = postsynaptic density protein 95.
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The normality of the data was confirmed by Kolmogorov-
Smirnov test for each group. Tests for equal variance were
done automatically by Prism as part of the statistical analysis;
variances were not statistically different between groups being
compared. For statistical analysis of the behaviour data, a re-
peated measures ANOVA was run on either the raw data
(distal middle cerebral artery occlusion beam test) or log-trans-
formed data (all other behaviour testing) followed by individ-
ual comparisons at each time point between vehicle- and
zolpidem-treated stroked animals. All other data were analysed
by either two-way ANOVA followed by Bonferroni post hoc
test, one-way ANOVA followed by post hoc Tukey test, two-
tailed Student’s t-test, or two-tailed Mann Whitney test as
indicated. P-values5 0.05 were considered statistically
significant.
Results
Transient increase in GABAA-Ra1-
containing synapses specific to layer 5
peri-infarct cortex
To investigate the structural synaptic changes induced in
layer 2/3 and layer 5a of the peri-infarct region, array tom-
ography was used to quantify different synapse subtypes
before and after stroke. Synapses were classified based on
the co-localization of pre- and postsynaptic markers known
to characterize the major subclasses of GABAA and glutam-
ate synapses, as defined in Table 1 (Fig. 1A) (Neumann-
Haefelin et al., 1998; Redecker et al., 2000). GABAergic
synapse density significantly increased (1.7-fold) at 1
week post-stroke in cortical layer 5a (Fig. 1B–D). The
stroke-induced increase in detectable GABAA-R1 contain-
ing synapses is layer-specific with a significant increase
observed in layer 5a with no significant change observed
in layer 2/3 (Fig. 1D). Furthermore, the increase in layer 5a
was transient, observable at 1 week post-stroke but return-
ing to baseline 1 month post-stroke (Fig. 1D). In contrast to
GABA synapses, stroke had no observable effect on the
density of the different glutamatergic synapse subclasses
investigated either in layer 5 (Fig. 1C) or layer 2/3, at 1
week or at 1 month post-stroke (data not shown).
Together, these data reveal that stroke-induced synaptic
changes in the peri-infarct cortex can be dynamic, cortical
layer-specific, and synapse class-specific.
Transient increase in GABAA
signalling specific to layer 5 neurons
To determine if the transient and layer-specific increase in
the number of GABAAR1-containing synapses observed
by array tomography was accompanied by a functional
increase in phasic GABAA signalling, we examined spon-
taneous IPSCs in neurons from control and stroke-injured
mice at 1 week and 1 month post-stroke. We performed
whole-cell patch clamp recordings in the peri-infarct cortex
from acute neocortical slice preparations. At 1 week post-
stroke the average charge of spontaneous IPSCs in layer 5
pyramidal neurons was increased in stroke-injured mice
(Fig. 2A–C and Supplementary Table 1). Cumulative prob-
ability plots of layer 5 pyramidal neuron spontaneous IPSC
properties revealed a significantly higher proportion of the
population with larger events present in the stroke-injured
mice, indicated by the rightward shift of the charge curve at
both low (51000 fC) and high (1000–8000 fC) values
(Fig. 2D). The increased charge of spontaneous IPSCs
could reflect an increase in the number of receptors and/
or an increase in spontaneous network activity. To deter-
mine if the increased charge is independent of changes in
network activity we used TTX to block action potential
firing and measured miniature IPSCs in these cells. We
found an increase in the charge of miniature IPSCs from
injured animals at 1 week post-stroke, which is consistent
with a postsynaptic change in the number of GABAergic
receptors (Supplementary Fig. 2). These results confirm that
there is a functional increase in the postsynaptic response
during phasic GABAA signalling. Interestingly, the conser-
vative increase in charge of miniature IPSCs is insufficient
to explain the relatively greater increase in spontaneous
IPSC charge after stroke. This suggests that in addition to
the increased postsynaptic GABA signalling observed with
isolated miniature IPSCs, a separate as-yet unidentified ac-
tivity-dependent mechanism(s) also contributes to the in-
crease in phasic inhibition after stroke.
Stroke-injured animals also displayed an increase in mean
spontaneous IPSC rise time (stroke: 1.10  0.09ms versus
control: 0.88  0.04ms, P = 0.04; Supplementary Table 1),
suggesting there is an increase in GABA signalling at more
distal sites from the cell body in the injured mice.
Consistent with the array tomography data, the increase
in pyramidal neuron phasic GABAA signalling after stroke
was cortical layer-specific as spontaneous IPSCs were not
changed in layer 2/3 pyramidal neurons at 1 week post-
stroke (Supplementary Table 1). Furthermore, the stroke-
induced increase in layer 5 pyramidal neuron phasic
signalling was transient, observed at 1 week but not at 1
month post-stroke (Fig. 2E and Supplementary Table 2).
Changes in GABA signalling were cell type-specific in
layer 5. The aforementioned changes were observed in pyr-
amidal cells while the major class of GABAergic inhibitory
cells, fast-spiking interneurons, did not exhibit post-stroke
changes in spontaneous IPSC amplitude, charge, or kinetics
at 1 week post-stroke (Supplementary Table 1), although
spontaneous IPSC frequency was increased (stroke:
3.50  0.58Hz versus control: 1.78  0.27Hz, P = 0.04;
Supplementary Table 1). The increase in spontaneous
IPSC frequency without concurrent increased spontaneous
IPSC amplitude or charge in fast-spiking neurons of layer 5
suggests there are additional mechanisms contributing to an
increase in phasic inhibition, such as increases in synapse
number, presynaptic release probability, or axonal excit-
ability (Hu and Jonas, 2014). The intrinsic excitability of
the L5 pyramidal and fast-spiking neurons, which can also
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affect the overall activity of the cells, was not different in
the stroke-injured mice compared with the controls
(Supplementary Tables 3 and 4).
An important factor affecting GABA-mediated inhibition
is the chloride ion (Cl) concentration gradient, which de-
termines the equilibrium potential (EGABA) for inhibitory
responses. Normally in the adult brain neuronal intracellu-
lar levels of Cl are low, resulting in inhibitory GABAA
responses. However, during development, and after some
injuries, intracellular levels of Cl increase so that GABAA
responses can lose their efficacy in inhibiting neural func-
tion (reviewed in Kaila et al., 2014). To determine if the
EGABA is altered after stroke, we used a non-invasive
method relying on cell-attached recordings that avoided
dialysis of intracellular Cl (Verheugen et al., 1999).
Using this method we measured the membrane potential
in L5 pyramidal neurons in response to GABA puff appli-
cation at 1 week post-stroke. We found that neither the
resting potential nor the evoked GABA responses were af-
fected in stroke-injured compared to control animals
(Supplementary Fig. 3 and Supplementary Table 5) suggest-
ing that EGABA is not affected by the lesion.
Together, these results suggest that there is overall
enhanced phasic GABA signalling in layer 5 of the peri-
infarct neocortex at 1 week post-stroke. Furthermore, cor-
tical layer- and cell-type specific postsynaptic changes in
layer 5 pyramidal neurons return to basal levels by 1
month, which are consistent with the changes in GABA
synapses observed by array tomography.
Post-stroke zolpidem treatment
improves behavioural recovery
To determine what effect enhanced phasic GABA signalling
during the repair phase might have on stroke recovery,
animals were treated with a low (subsedative) dose of zol-
pidem, a GABAA positive allosteric modulator with high
affinity for 1-containing GABAA receptors (Crestani
et al., 2000). Zolpidem treatment was started on Day 3
post-stroke (i.e. subacute phase) (Fig. 3B). As the stroke
lesion mainly affects the somatosensory cortex (Fig. 3A),
the adhesive tape removal test was used to monitor func-
tional recovery as it gives a measure of forelimb
Figure 1 Stroke induces cortical layer-specific changes in GABA synapses. (A) Representative array tomography image for GABA
synapses: synapsin (red), VGAT (green), GABAAR1 (blue). Yellow circles mark triple co-localization. Co-localization with GAD is omitted for
clarity. Scale = 200 nm. (B) Schematic illustrating the brain region used to analyse synapses. Grey indicates cortical lesion; red box indicates the
peri-infarct cortical region taken for synapse analysis. (C) Array tomography quantification of GABA and glutamate synapse subtypes in layer 5a
peri-infarct cortex at 1 week post-stroke reveals a significant increase in the number of GABA synapses. (D) Array tomography quantification of
GABA synapses in different cortical layers and at different time points after stroke. For C and D, n = 6 animals per group at 1 week, n = 5 animals
per group at 1 month. *P5 0.05; **P5 0.01 [t-test used in C and for layer 5 comparison in stroke animals (D); two-way ANOVA (P = 0.0033),
with Bonferroni post hoc analysis, used for comparison of the four groups at 1 week in D]. Data shown as mean  SEM.
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sensorimotor function. Following stroke, the time taken for
the animals to contact the adhesive tape on their affected
(contralesional) forelimb increased (Fig. 3C); this deficit
was maximal at 2 days post-stroke and recovered spontan-
eously to baseline within 1 month post-stroke. Chronic
treatment with a low dose of zolpidem rapidly enhanced
functional recovery (P5 0.01 by repeated measures
ANOVA) with the effect observed as early as 4 days
from treatment onset (i.e. 7 days post-stroke) (Fig. 3C).
The time to remove the tape from the affected forelimb
was similar in stroke-injured and control animals
(Supplementary Fig. 4A); lack of a significant effect on
this motor function aspect of the test is consistent with
the motor cortex being largely intact. Use of the unaffected
(ipsilesional) forelimb (Supplementary Fig. 4B and C) was
unchanged by stroke or zolpidem treatment. In the rotating
beam behaviour test, stroke caused a small but significant
impairment in speed (P = 0.003, Day 0 versus Day 2). This
deficit recovered to baseline by Day 14 in both groups and
zolpidem treatment significantly enhanced the rate of recov-
ery (Fig. 3D). Zolpidem treatment starting on Day 3 had
no effect on lesion size at Day 7 post-stroke compared to
vehicle-treated animals (vehicle group lesion size:
25.8%  6.1% of ipsilesional cortex; zolpidem group:
24.2%  4.8% of ipsilesional cortex). This is in contrast
to treating animals with GABAA receptor agonists at stroke
Figure 2 Stroke enhances postsynaptic inhibitory currents in layer 5 pyramidal neurons. (A and B) Spontaneous IPSC recordings
from representative layer 5 pyramidal neurons from (A) control and (B) stroke-injured mice. (C) Ensemble-averaged IPSCs from the same
pyramidal cells (control, black; injured, red). Spontaneous IPSC charge is calculated as the total area under the curve (purple). Inset: Action
potential firing induced by an intracellular current injection in the pyramidal cell. Firing pattern was used to distinguish pyramidal cells from fast-
spiking interneurons. (D) Cumulative probability histograms of isolated events at 1 week post-stroke from 10 slices from five control mice
(n = 1500 events, 15 cells, 100 events per cell) and eight slices from five injured mice (n = 1100 events, 11 cells, 100 events per cell) reveal a higher
proportion of events with larger charge present in the stroke-injured mice, demonstrated by the right shift of the charge curve at low values
(charge5 1000 fC; indicated by single arrow) and the divergence of the charge curves especially at high values (inset: magnified portion of the plot
between 1000–8000 fC; double arrow) (P = 0.005; Kolmogoroff-Smirnoff test). (E) Cumulative probability histograms of the charge of isolated
events at 1 month post-stroke from nine slices from four control mice (n = 1300 events, 13 cells, 100 events per cell) and eight slices from four
injured mice (n = 2300 events, 23 cells, 100 events per cell) are not different at low values (charge5 1000 fC; single arrow). Inset displays a
leftward shift (not significant) at high values (charge 1000–8000 fC, indicated by the dagger) 1 week post-stroke (P = 0.08; Kolmogoroff-Smirnoff
test).
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onset, which is known to decrease lesion size (Lyden and
Hedges, 1992; Green et al., 2000), and which we also
observed when zolpidem was administered at stroke onset
(Supplementary Fig. 5). These data indicate that enhancing
phasic GABAergic signalling in the repair phase, starting 3
days after stroke, improves functional recovery without
being neuroprotective.
We used a second stroke model, the photothrombotic
model, to determine if the recovery-enhancing effects of
zolpidem are complementary across different stroke
models. In this model the lesion was primarily in the
motor cortex (Fig. 4A), and resulted in much larger deficits
in both the tape and beam tests than the previous stroke
model (distal middle cerebral artery occlusion model)
(Fig. 4B–D). In the tape test, stroke induced a significant
deficit in the time to both contact and remove the tape
from the affected limb (Fig. 4B and C). Animals treated
with zolpidem exhibited a trend for improved recovery
on both parameters. Zolpidem significantly enhanced the
rate, but not extent, of recovery for tape contact, with
greater recovery observed at Day 7 post-stroke in the zol-
pidem group; this differential recovery between the two
groups dissipated at later time points. For tape removal,
the effect of zolpidem was observed later with a trend for
increased recovery seen from Days 14 to 28. In the rotating
beam test, photothrombotic stroke caused a very large im-
pairment of speed. Zolpidem had no effect on recovery
(Fig. 4D), which may suggest that a certain threshold of
innate (spontaneous) recovery is required for zolpidem to
be effective. Zolpidem did not affect lesion size. Together,
the data from the two stroke models show that zolpidem
treatment in the repair phase of stroke can enhance recov-
ery, with the most prominent effect being an accelerated
rate of recovery.
Post-stroke zolpidem treatment
enhances GABAA signalling
As zolpidem is a positive allosteric modulator it would fur-
ther augment the stroke-induced increase in phasic
Figure 3 Zolpidem treatment enhances behavioural recovery after stroke. (A) A representative TTC-stained stroke-injured brain
showing the lesion location (white: upper panel) mapped to the corresponding brain schematics (lower panel) taken from the Mouse Brain Atlas
(Paxinos and Franklin, 2004) showing that the lesion (grey) is primarily in the somatosensory cortex (S1, S2). (B) Timeline indicating treatment
paradigm. Short black arrows indicate behaviour testing days. (C) Zolpidem treatment starting at 3 days after distal middle cerebral artery
occlusion-induced stroke enhanced functional recovery as assessed by the forelimb adhesive dot removal test. Pooled data from three experi-
ments, each of which individually gave similar results; n = 15 (stroke/vehicle), n = 16 (stroke/zolpidem), and n = 7 (each sham group). Repeated
measures two-way ANOVA (P = 0.0072). *P5 0.05, **P5 0.01 for stroke + vehicle versus stroke + zolpidem. (D) Zolpidem treatment
enhanced the rate of recovery in the rotating beam test; n = 5 per group. Repeated measures two-way ANOVA (P = 0.0499). ***P5 0.001 by
Bonferroni post hoc test. Data shown as mean  SEM. AI = agran insular cortex; AuV = second auditory cortex; CC = corpus callosum;
Cl = claustrum; Ect = ectorhinal cortex; fmi = forcepts minor corpus callosum; I = insular cortex; Lo = lateral orbital cortex; M1 = primary motor
cortex; M2 = secondary motor cortex; Prh = perihinal cortex; S1 = primary somatosensory cortex; S1BF = S1 cortex, barrel field; S1FL = S1
cortex, forelimb; S1HL = S1 cortex, hindlimb; S1Tr = S1 cortex, trunk; S2 = secondary somatosensory cortex.
Phasic GABA promotes post-stroke brain repair BRAIN 2016: 139; 468–480 | 475
inhibition we observed during the repair phase. However,
this might lead to a compensatory downregulation in
GABAARs. Retention of full GABAAR function under
these conditions would support the hypothesis that the in-
crease in phasic inhibition observed after stroke is beneficial
to functional recovery. To address this issue we examined
spontaneous IPSCs in layer 5 of the peri-infarct cortex at
Day 7 post-stroke from animals treated with zolpidem or
vehicle starting at 3 days post-stroke, and subjected to 1
week of behaviour testing. Brain slices were made from
zolpidem- and vehicle-treated animals, and incubated in
zolpidem-free artificial CSF for42 h during spontaneous
IPSC recording, removing any extracellular zolpidem. In
zolpidem-treated animals, compared to the vehicle-treated
group, spontaneous IPSCs exhibit increased frequency,
amplitude and charge in layer 5 pyramidal neurons
(Fig. 5) but not in fast-spiking interneurons (data not
shown). Zolpidem-treatment did not alter the intrinsic ex-
citability of pyramidal neurons or fast-spiking interneurons
(Supplementary Table 6) suggesting that changes in
spontaneous IPSC properties induced by zolpidem treat-
ment are a result of changes in synaptic function rather
than altered intrinsic excitability of neurons. In summary,
our results indicate that the behavioural recovery induced
by zolpidem treatment is associated with an enhanced
phasic (synaptic) GABA signalling in excitatory pyramidal
neurons but not in inhibitory neurons within layer 5 of the
peri-infact area.
Discussion
Cortical circuit plasticity and remapping is important for
functional recovery after stroke (Nudo et al., 1996;
Dijkhuizen et al., 2001; Carmichael, 2006; Murphy and
Corbett, 2009). Emerging evidence points to a role for
GABA-mediated inhibition in modulating post-stroke plas-
ticity as shown in a study where decreasing tonic (extra-
synaptic) GABA inhibition in the repair phase of stroke,
which starts days after stroke onset (Carmichael, 2006; Li
Figure 4 Effect of zolpidem treatment on recovery in a photothrombotic model of stroke. (A) Representative Cresyl violet-stained
sections at 35 days post-stroke (upper panel) mapped to the corresponding brain schematics (lower panel) taken from the Mouse Brain Atlas
(Paxinos and Franklin, 2004) showing that the lesion (grey) is primarily in the motor cortex (M1, M2). (B–D) Effect on recovery of zolpidem
treatment starting at 3 days post-stroke as measured by (B and C) the adhesive tape test, and (D) the rotating beam test. Pooled data from four
experiments, each of which individually gave similar results; n = 17 per group. *P5 0.05 by two-tailed Mann–Whitney test. Data shown as
mean  SEM. Cg = cingulate cortex; M1 = primary motor cortex; M2 = secondary motor cortex; PtA = parietal association cortex;
RS = retrosplenial cortex; S1FL = S1 cortex forelimb; S1HL = S1 cortex, hindlimb; S1Tr = S1 cortex, trunk.
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et al., 2010), significantly improved functional recovery
(Clarkson et al., 2010). Much less is known about the
role of phasic (synaptic) inhibition, a second mode of
GABA signalling, in the repair phase of stroke. Our study
provides the first structural and functional evidence of
enhanced phasic GABAergic signalling in the peri-infarct
cortex during the repair phase. Importantly, we demon-
strate that boosting phasic GABA in the repair phase,
using zolpidem, an FDA-approved positive allosteric
GABA modulator, enhanced functional recovery without
affecting lesion size. Thus, we identified a novel therapeutic
strategy for stroke that targets plasticity-related recovery.
Phasic GABA signalling is driven by synaptic GABAARs
(as opposed to extrasynaptic GABAARs that drive tonic
signalling) (Farrant and Nusser, 2005). GABAARs contain-
ing the 1 subunit are the most highly expressed GABAAR
in the mammalian brain (Fritschy and Mohler, 1995) and
mediate the majority of phasic inhibition. Using array tom-
ography, a high resolution imaging method (Micheva and
Smith, 2007; Micheva et al., 2010) that overcomes the
inherent difficulties of imaging synapses, we found a sig-
nificant increase in the number of GABAergic synapses with
1-subunit-containing receptors. This increase was cortical
layer-specific—observed in layer 5 but not in layer 2/3—
and transient, occurring during the onset of functional re-
covery and returning to baseline after 1 month. In contrast,
we observed no change in the number of glutamatergic
synapses. Previous published measurements of GABAAR
protein expression suggested a decrease in the number of
GABAergic synapses at a similar time point (Schiene et al.,
1996; Neumann-Haefelin et al., 1998; Qu et al., 1998;
Redecker et al., 2000; Jolkkonen et al., 2003). These dif-
ferences may be due to the various regions of interest and
techniques used. Some studies used autoradiography meas-
urements of 3H-muscimol binding (a GABA agonist that
binds at the same site as GABA) to assess GABAAR density
(Schiene et al., 1996; Qu et al., 1998; Jolkkonen et al.,
2003). However, muscimol binding will reflect its distinct
affinities for different GABAAR subtypes, and there is
debate whether muscimol even binds to 1 subunit recep-
tors (Chandra et al., 2010). Other studies used immunohis-
tochemical analysis of different GABAAR subunits,
including 1, to assess GABAA receptor expression in indi-
vidual cortical layers (Neumann-Haefelin et al., 1998;
Redecker et al., 2000). However, this method measures
global protein expression, which could mask what is occur-
ring at the synapse. In contrast, array tomography enables
quantitative measurements specifically at the level of the
synapse.
Intracellular whole-cell recordings confirmed a functional
increase in phasic GABAAR-mediated signalling in the peri-
infarct after stroke with the same temporal profile and
cortical layer specificity observed for the aforementioned
structural synaptic changes. We found that spontaneous
Figure 5 Zolpidem treatment enhances postsynaptic inhibitory currents in layer 5 pyramidal neurons. (A and B) Spontaneous
IPSC recordings from representative layer 5 pyramidal neurons from stroke-injured mice treated with (A) vehicle and (B) zolpidem. (C)
Ensemble-averaged spontaneous IPSCs from the same pyramidal cells (vehicle, black; zolpidem, red), plotted on the same timescale. (D–F)
Cumulative probability histograms of isolated events from seven stroke-injured vehicle-treated mice (n = 1300 events, 13 cells, 100 events per
cell) and six stroke-injured zolpidem-treated mice (n = 800 events, eight cells, 100 events per cell) demonstrate differences in frequency, charge
and amplitude of the events (Frequency, P = 1024; Charge, P = 106; Amplitude, P = 108; Kolmogoroff-Smirnoff test).
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IPSCs were increased in layer 5 pyramidal neurons but not
in layer 2/3 pyramidal neurons. These data suggest the
postsynaptic properties of pyramidal neuron GABAergic
synapses are enhanced after stroke. This was further corro-
borated by finding a stroke-induced increase in the charge
of miniature IPSCs in layer 5 pyramidal neurons. Although
GABAA-R 1 is known to be highly expressed in layer 5
fast-spiking interneurons (Bacci et al., 2003), there was no
change in the charge, amplitude, or kinetics of spontaneous
IPSCs recorded from these cells. However, we observed an
increase in frequency of layer 5 fast-spiking interneuron
IPSCs. These observations suggest additional mechanism(s)
enhance phasic GABAergic signalling in fast-spiking inter-
neurons different from those that enhance GABAergic sig-
nalling in pyramidal neurons during the repair phase of
stroke; these mechanisms remain to be elucidated. The in-
dividual consequences of these layer- and cell-specific
changes in GABAergic inhibition on network activity, and
the specific microcircuits affected, remain to be determined.
Given that different populations of cells within different
cortical layers have separate functions, it is likely that
changes in GABAAR synapses onto distinct GABAergic
interneurons and glutamatergic pyramidal cells will have
diverse actions within local cortical circuits (Salin and
Prince, 1996; Bacci et al., 2003).
As layer 5 pyramidal neurons provide the major source
of output from the cortex we anticipated that the post-
stroke changes in phasic GABA activity onto these cells
would affect post-stroke sensory and motor function. One
might hypothesize that phasic GABA signalling, like tonic
GABA, is detrimental to post-stroke plasticity and recovery
(Schiene et al., 1996; Neumann-Haefelin et al., 1998; Qu
et al., 1998, Redecker et al., 2000; Jolkkonen et al., 2003).
However, phasic GABA drives cortical plasticity and
remapping in the neonatal and postnatal brain (Zheng
and Knudsen, 2001; Derdikman et al., 2003; Fagiolini
et al., 2004; Hensch and Stryker, 2004; Foeller et al.,
2005; Hensch, 2005; Mendez and Bacci, 2011; Lehmann
et al., 2012). As post-stroke brain repair processes may
recapitulate developmental GABAAR-mediated plasticity
(Li et al., 2010; Mendez and Bacci, 2011; Lehmann
et al., 2012), we speculated that phasic GABA activity
could actually promote post-stroke plasticity-related recov-
ery. Indeed, post-stroke increases in phasic GABAergic ac-
tivity occur within the first week after stroke, which is
when cortical map plasticity is thought to start in rodents
(Carmichael, 2006; Li et al., 2010). Moreover, we found
that potentiating phasic GABA signalling during the repair
phase, by treatment with a low dose of the GABAA-R1
allosteric modulator zolpidem, significantly improved func-
tional recovery in two models of stroke recovery. Of note,
chronic treatment with zolpidem only enhanced phasic
GABA signalling in layer 5 excitatory (pyramidal) neurons
but had no effect on layer 5 inhibitory (fast-spiking) inter-
neurons, suggesting treatment-induced plasticity is cell-type
specific. Unlike GABA agonist treatment at stroke onset,
which can be neuroprotective (Lyden and Hedges, 1992;
Green et al., 2000), our delayed zolpidem treatment para-
digm, starting 3 days after stroke, did not affect lesion size.
These data support the idea that enhanced phasic GABA A-
R1 signalling in the repair phase promotes plasticity-
related recovery and presents a novel therapeutic strategy.
Furthermore, our data identify zolpidem as a pharmaco-
logical agent to treat stroke. Zolpidem is an FDA-approved
sleep aid, better known as Ambien, and therefore offers the
potential of a tested and safe pharmacological agent to
treat stroke. The low doses of zolpidem used in our study
are below that required for sleep and do not induce drow-
siness. Case studies show subsedative doses of zolpidem can
improve motor and cognitive recovery after brain injury,
including stroke (Cohen et al., 2004; Shames and Ring,
2008; Hall et al., 2010). This is often coincident with
increased blood flow to the injured hemisphere after zolpi-
dem treatment, suggestive of increased brain activity, and
with desynchronized beta oscillations in the motor cortex, a
known prerequisite for movement (Cohen et al., 2004; Hall
et al., 2010). There are suggestions that the 1 subunit spe-
cificity of zolpidem in this setting is an important component
of its reparative function as other benzodiazepine site ligands
do not have the same effect (Shames and Ring, 2008; Hall
et al., 2010). Our data have strong therapeutic implications
as there are currently no FDA-approved drugs that target the
brain repair phase of stroke or other CNS injuries.
Zolpidem binds with high affinity to the 1 subunit and
with 10-fold lower affinity to 2 and 3 subunits.
Therefore, we cannot rule out the involvement of other
GABAAR subunits in promoting recovery after stroke.
Indeed, our electrophysiology data suggest that in addition
to GABAARs containing the 1 subunit, GABAAR’s con-
taining other subunits also increase after stroke.
1-containing GABAARs have rapid decay kinetics; accord-
ingly if only 1-containing GABAARs increased we would
expect to see an increase in miniature or spontaneous IPSC
amplitude with a decrease in duration. However, we
observed an increase in charge with no significant change
in amplitude and kinetics. These findings suggest changes in
other GABAAR subunits after stroke, in addition to 1,
may contribute to the enhanced phasic GABA signalling.
Identifying which additional subunits are altered and their
potential involvement in functional recovery is an import-
ant focus for future studies.
A beneficial role of phasic GABA is in contrast to the
detrimental role of tonic GABA signalling in post-stroke
recovery (Clarkson et al., 2010) and challenges the idea
that enhanced GABA function is generally detrimental
after stroke. This is not the first account of phasic and
tonic inhibition mediating opposing outcomes. In absence
epilepsy, agents that enhance tonic inhibition exacerbate
seizures (Perucca et al., 1998), while benzodiazepines that
enhance phasic inhibition are effective antiepileptic drugs
(Mikkelsen et al., 1976; Huguenard and Prince, 1994).
Our data offer a fresh perspective on GABA’s role in
brain repair after stroke. It also raises the intriguing ques-
tion of why the brain activates two opposing actions in a
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similar time frame. A balance between promoting and in-
hibiting plasticity is likely important to prevent maladaptive
plasticity, which could induce stroke-related epilepsy, while
still driving brain repair. The increase in phasic GABA sig-
nalling we observed is predominantly in cortical layer 5, the
main source of cortical output, with very little effect seen in
layer 2/3, the major source of interhemispheric cortico-cor-
tical connections. Tonic GABA signalling, by contrast, is re-
ported to be significantly altered in layer 2/3 (Clarkson et al.,
2010). This cortical layer specificity suggests that distinct
cortical microcircuits respond differently after stroke.
However, the significance of this and the interplay between
phasic and tonic GABA in modulating stroke recovery
remain to be determined. Moreover, as the GABAA receptors
that mediate phasic and tonic inhibition differ in their sub-
unit composition—phasic GABAARs contain primarily 1-
3,5 subunits whereas tonic GABAARs contain primarily
4,6 subunits (Farrant and Nusser, 2005; Glykys et al.,
2008; Rudolph and Knoflach, 2011; Hines et al., 2012)—
it highlights the importance of targeted pharmacological
intervention when considering therapeutic strategies for
stroke that modulate GABA signalling.
In conclusion, our study provides the first account of
increased phasic GABA activity in the early weeks follow-
ing stroke injury and demonstrates that enhancing phasic
GABA signalling in the repair phase with an FDA-approved
drug promotes post-stroke functional recovery. Taken to-
gether our data offer new insights into mechanisms of brain
repair and identify a novel therapeutic strategy and
pharmacological target for stroke. Furthermore, our obser-
vations emphasize the necessity to distinguish the role of
phasic and tonic GABA inhibition in stroke recovery as
well as in normal brain functions.
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